PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector
|
|
- Tracey Anthony
- 6 years ago
- Views:
Transcription
1 PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector
2 Content Answer industry questions related to the PSMF MHRA inspector s preparation: How we use the PSMF Questions and areas for further discussion 2
3 Disclaimer This material represents the view of the MHRA. I m not going to answer detailed questions about individual MAH scenarios during Q&A. EMA have published Q&As Update November 2012: egulatory_and_procedural_guideline/2012/05/wc pdf 3
4 Your Questions Answered! 8
5 Location and Registration (1) Where should the PSMF be located if the QPPV is a one person contractor in the UK and all PV activities are conducted outside EEA? Should the PSMF reside with the QPPV in his/her home? GVP Module II, the PSMF shall be located within the EU, either at the site where the main pharmacovigilance activities are performed or at the site where the qualified person responsible for pharmacovigilance operates. If no other site qualifies, this may include a private residence. 9
6 Location and Registration (2) Does a new PSMF location require a new MFL number in XEVMPD? EMA guidance document on XEVPRM: the extended EudraVigilance medicinal product report message (version 3.2): Published 31 Jan 2014 and effective 16 June nt_listing/document_listing_ jsp&mid=wc0b01ac c Variations to the information on PSMF location may trigger the generation of new EV Codes. 10
7 Location and Registration (3) If the PSMF is located in another EU country (outside the UK) does that mean that we are less likely to be inspected by the MHRA? According to GVP Module III, scheduling routine inspections should be according to a risk-based methodology. MHRA does not account for PSMF location when scheduling national inspections. They can be scheduled at anytime. The scope of MHRA inspections may be tailored to account for inspections conducted by other NCAs including by the Supervisory Authority (if applicable). 11
8 Inspection Planning (1) How do MHRA Inspectors use the PSMF? The section on organisational structure and annex B (contracts) can help to determine the scope and length of the inspection. The section on pharmacovigilance processes describes how pharmacovigilance activities are performed, and aids preparation of the inspection plan. The PSMF can be used to establish what studies, registries or other programmes are on-going. A list may be provided in annex C or may have to be requested. 12
9 Inspection Planning (2) How do MHRA Inspectors use the PSMF? The section on Pharmacovigilance System Performance is key. Are regulatory reporting obligations being met? The section on Quality System may contain notes associated with audits where significant findings are raised. MHRA inspectors routinely check whether corrective and preventative actions are within proposed resolution dates. 13
10 EEA QPPV Do changes in QPPV contact details require a variation? Once it becomes fully functional, changes in QPPV contact details (telephone, address and ) may be updated through the Article 57 database (without a variation). Currently, changes require a type IA IN variation. What should be included in the summary CV in the body text? Abbreviated details (name, contact information and qualification) The full CV should be included in Annex A. 14
11 Organisational Structure and Annex B: Contracts Which sub-contracted/ delegated activities should be included in the list? Can it be limited to agreements at corporate level? GVP guidance includes: distributors, licensing partners, co-marketing partners medical information, auditors, PSP and data management other technical providers (e.g. hosting of computer systems). Not just limited to corporate level agreements. Worldwide agreements which are applicable to EU authorised product, including agreements entered by affiliates must also be described. 15
12 Sources of Safety Data (1) What is the expectation for the description of main units collecting safety data? The body text description may be brief. It should highlight the main units (or types of unit) where safety data may originate on a global basis. This may include affiliates, medical information centres, studies, registries or surveillance programmes. The Annex C lists should be comprehensive and describe the country, nature of the activity, products and site contact details. 16
13 Sources of Safety Data (2) Does the MHRA expect to see lists of studies, registries, surveillance or support programmes in Annex C? GVP Module II: Lists of studies and support programmes may be located in an Annex or provided separately. Findings would not be raised if these lists were not included. The guidance indicates that the MAH must be able to provide such lists for inspection purposes. They will routinely be requested by MHRA Inspectors. It is preferable (not mandatory) that they are included in the PSMF. 17
14 Computerised Systems (1) Besides the safety database, which other systems or databases need to be described? Any MAH system used to receive, collate, record and report safety information. This might include: medical information systems product quality databases clinical trial systems any system important for the collection of safety data. An element of judgment is involved. 18
15 Computerised Systems (2) What should be included in Annex D of the PSMF Computerised Systems? There is limited guidance in GVP. The body text should provide descriptive information about the location, functionality (including validation status) and operational responsibility for computerised systems. Annex D can be used to provide tabular information about those systems. 19
16 Pharmacovigilance Processes Is it acceptable to simply list the documented procedures of the MAH or is something further required? A description of the following processes should be included: Continuous monitoring of risk-benefit profile(s) Risk management system(s) ICSR collection, collation, follow-up and reporting PSUR scheduling, production and submission Communication of safety concerns Implementation of safety variations 20
17 Pharmacovigilance System Performance (1) Case processing is delegated to a vendor. The vendor maintains KPIs to monitor the quality of ICSRs. Should this be provided to the MAH for inclusion in the PSMF? The MAH and QPPV should monitor the quality of ICSRs. A description of quality monitoring must be included in the PSMF. If the MAH monitors quality using metrics then these should be supplied in the PSMF. The MAH may delegate aspects of quality to the vendor (but retains responsibility). If the MAH uses the vendor quality metrics for its own purpose then these should be in the PSMF. 21
18 Pharmacovigilance System Performance (2) What are the expectations regarding the performance indicator targets for ICSR and PSUR submission compliance? There is no defined acceptable level of non-compliance. Targets can only reasonably be defined depending upon the volume of submissions within your organisation. As a general rule, ICSR expedited reporting compliance which drops below 95% may raise questions during inspection. PSUR submission targets are harder to define. In a small organisation, one missed PSUR may represent 100% failure. 22
19 Quality System: Audits (1) Questions about the inclusion of audit findings and deviations in the PSMF was the most popular topic from delegates. Article 104(2) of the Directive: The marketing authorisation holder shall perform a regular audit of his pharmacovigilance system. He shall place a note concerning the main findings of the audit on his pharmacovigilance system master file. The legal requirement only relates to audits conducted or commissioned by the MAH on its own system. 23
20 Quality System: Audits (2) If the MAH conducts an external audit of a partner or contractor, do the major and critical findings need to be recorded in the MAH PSMF? Yes. This audit is conducted or commissioned by the MAH. This is an example of an audit of the MAH s PV system, as the partner/ contractor is performing activities on behalf of the MAH (this may only include case collection in a single territory). The MAH is not the CAPA owner but CAPA implementation should still be confirmed or verified by the MAH. 24
21 Quality System: Audits (3) Do major and critical findings identified during an audit of the MAH by a partner company need to be recorded in the MAH PSMF? No. The audit is not conducted or commissioned by the MAH. It is not mandatory to include the findings identified by partners in the MAH PSMF. However, the MAH is encouraged to include significant findings (to the extent that they are relevant to the MAH s PV system). The result of partner audits could be an input to the MAH s own risk-based audit planning. As a result the MAH may trigger its own internal audit. 25
22 Quality System: Audits (4) A vendor identifies critical or major findings through its own internal audit. Do these findings need to be recorded in the MAH PSMF? No. The legal requirement for PSMF inclusion relates to audits conducted or commissioned by the MAH. The MAH should be notified of relevant non-compliance identified by the vendor and this should be stipulated in the contract with the vendor. The findings should be inputs into the MAH s own risk-based audit planning. As a result the MAH may trigger its own vendor audit. 26
23 Quality System: Audits (5) Do open CAPA from Competent Authority Inspections need to be included in the PSMF? GVP guidance is only applicable to audit findings and deviations. NCAs routinely have access to inspection findings from other Member States through information sharing processes. It can be helpful [but is not mandatory] to include open CAPA from NCA inspection in the PSMF. 27
24 Quality System: Audits (6) Can audit findings be included in the PSMF annex rather than the body text? It is easier the manage the addition and removal of annex information. The EU legal interpretation is that the note should be in the PSMF body text. The addition, amendment or removal of audit notes must be recorded in the logbook. Only body-text sections are subject to logbook control. Recording removal in the logbook verifies that sufficient improvement has been demonstrated or independently verified. 28
25 Quality System: Deviations Do all deviations or only those equivalent to major and critical need to be described in the PSMF? The PSMF shall document deviations from pharmacovigilance procedures (including impact) until they are resolved. There is no additional guidance in GVP. MHRA would not expect to see every single SOP deviation recorded in the PSMF (although repeat deviations to the same process may indicate an underlying issue). Both planned and unplanned deviations should be considered. An element of judgment is involved. 29
26 Annex G: Audit Schedule Should the Annex G audit schedule also include the internal audit plans of partner companies? No. The intention is to give an overview of audits planned and conducted by the MAH (including those conducted by an external auditor on behalf of the MAH). 30
27 Annex H: Product List (1) Annex H requires information about products and their presence on the market. What exactly is required? A product which was last shipped to a country may still be on the market with a long shelf-life. Annex H should include a list of products covered by the pharmacovigilance system master file. A product is considered to be on the market whilst it remains available to patients i.e. during its shelf-life. Pharmacovigilance requirements continue as long as a product is on the market. GVP Module VI includes requirements and recommendations for products which have been suspended (or withdrawn). 31
28 Annex H: Product List (2) MAH 1 places its products on the market but uses the system of MAH 2 to fulfil its pharmacovigilance obligations. Which PSMF should cover the relevant products? The product should be included in the PSMF of MAH 2 (i.e. the pharmacovigilance system in which it resides). MAH 1 should make reference to the additional PSMF in the annex of its own PSMF. Thus the entire MAH product portfolio can be related to the set of pharmacovigilance system master files. 32
29 Logbook To what extent should changes be recorded in the logbook? The Commission Implementing Regulation states that the MAH shall record any alteration of the content of the [PSMF] made within the last five years, with the exception of the information referred to in point 1(b) to (e) of Article 2 and in Article 3. It is not considered necessary log-book minor formatting changes such as typos and grammatical errors. 33
30 Version Control (1) Does a change to the annex require an immediate change in PSMF version number? Annex information may change rapidly and can be managed outside of the PSMF. Change history for the annex information should be available on demand. PSMF content and annex information may be independently versioned. 34
31 Version Control (2) Can changes to annex information be introduced periodically rather than immediately after each change? The PSMF is a living document and may constantly change. If requested by a NCA, the PSMF must be submitted within 7 days and it should be up-to-date at the time of submission. It is understood that some companies have implemented a quarterly revision cycle. This may be acceptable as long as an up-to-date version can be provided on request (i.e. in 7 days). 35
32 Your Questions Answered (hopefully).. 36
33 Crown copyright 2014 About copyright All material created by the MHRA, including materials featured within these MHRA presentation notes and delegate pack, is subject to Crown copyright protection. We control the copyright to our work (which includes all information, database rights, logos and visual images), under a delegation of authority from the Controller of Her Majesty s Stationery Office (HMSO). The MHRA authorises you to make one free copy, by downloading to printer or to electronic, magnetic or optical storage media, of these presentations for the purposes of private research, study and reference. Any other copy or use of Crown copyright materials featured on this site, in any form or medium is subject to the prior approval of the MHRA. Further information, including an application form for requests to reproduce our material can be found at Material from other organisations The permission to reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright holders concerned. 37
Fourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation
Fourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation Module II - Pharmacovigilance system master file Presented by: Joanna Harper Inspections, Enforcement & Standards
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/816573/2011 Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file Draft finalised by the Agency in collaboration with Member States and submitted
More informationThird Stakeholders forum on the implementation of the new Pharmacovigilance legislation
Safeguarding public health Third Stakeholders forum on the implementation of the new Pharmacovigilance Pharmacovigilance system master file an approach towards system simplification Joanna Harper Inspections,
More informationGuideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File
Guideline on Good Pharmacovigilance Practices Module V- Pharmacovigilance System Master File Turkish Medicines and Medical Devices Agency 16.02.2015 CHAPTER I... 2 1.1. Introduction... 2 CHAPTER II...
More informationPharmacovigilance Inspection Metrics Report
Pharmacovigilance Inspection Metrics Report April 2016 - March 2017 1. Introduction During the period 01 April 2016 to 31 March 2017, the GPvP Inspectorate conducted 36 inspections of marketing authorisation
More informationThe Pharmacovigilance Quality System. What is it?
The Pharmacovigilance Quality System What is it? by Andy Blackman 12 November 2018 Are you starting to plan your first Marketing Authorisation Application? If yes, now is the time to start developing your
More informationII.B.4. Information to be contained in the PSMF/ PSSF
II.B.4. Information to be contained in the PSMF/ PSSF No. PSMF/ PSSF section Remarks Cover Page: 1- The unique number (Revision No.) 2- The name of the MAH, QPPV or LSR (including third party). 3- The
More informationStakeholder Meeting, 17 June 2011, EMA, London. Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency
New Pharmacovigilance Legislation and Implementing Measures Minimum Requirements for Quality Systems (MAH, EMA, NCA), minimum requirements for Pharmacovigilance System Master File Stakeholder Meeting,
More informationBuilding Quality Metrics. Mark Birse, Deputy Director & Head of Inspectorate
Building Quality Metrics Mark Birse, Deputy Director & Head of Inspectorate Indicators of mature Quality Culture: Led from the top, empowered from below Communication of priorities To personnel To shareholders
More informationAgenda item 4.1 Draft proposal - Notifications of the location of the Pharmacovigilance System Master File (PSMF)
EMA Implementation Working Group with EU Pharmaceutical Industry Associations on the implementation of Article 57(2), second subparagraph of Regulation (EC) 726/2004 Agenda item 4.1 Draft proposal - Notifications
More informationImplementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories
Implementation and Impact of the PV Regulations - how are we doing? Sue Rees Eisai Europe Ltd. & John Barber, Dr Reddy's Laboratories Agenda PSMF PSURs Solicited sources RMPs Inspections Signal detection
More informationMHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents
MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015 Complex Business Models - Outsourced Activities Presented by: Jacqueline Masayi, GDP Inspector Background Increased complexities of the
More informationRole of International PVQA. Allison Jack, PVQA Director, GSK 24 th October 2017, Milan
Role of International PVQA Allison Jack, PVQA Director, GSK 24 th October 2017, Milan Agenda What does Regulations say about audits? Expectations of PVQA Organisation of PVQA What qualifications does a
More informationQuality Management in PV. Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017
Andrea Lohée, Pharm-AD DCVMN training on PV, May 2017 - Pharmacovigilance System - Overall Quality objectives in PV - Quality Management System overview - Quality Management System requirements - Quality
More informationTrends in pharmacovigilance inspection deviations. 8th Scandinavian SARQA/DKG Quality Assurance Conference
Trends in pharmacovigilance inspection deviations 8th Scandinavian SARQA/DKG Quality Assurance Conference Thorsten Jørgensen, PV Auditor, LEO Global Quality 1 Disclaimer This presentation does not represent
More informationGuidelines for Pharmacovigilance Inspections
PHARMACY BOARD OF SIERRA LEONE Guidelines for Pharmacovigilance Inspections Guideline No. : PBSL/PVGCT/GDL/QPPV/04-2017 Effective Date. :27 th March, 2017 Version No. : 01 1 TABLE OF CONTENT TABLE OF CONTENT
More informationConcept paper submitted for public consultation. SANCO/D3/FS/cg/ddg1.d.3(2011)
07 Nov 2011 Comments on: Implementing measures in order to harmonise the performance of the pharmacovigilance activities provided for in Directive 2001/83/EC and Regulation (EC) No 726/2004 Concept paper
More informationSafety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington
Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington DISCLAIMER These materials have been prepared solely for educational
More informationGood Documentation Practice Session 2
Good Documentation Practice Session 2 Good Documentation Practice A refresher EU GMP Chapter 4: Documentation Required GMP documentation: Site Master File Instructions: Specifications Manufacturing Formulae,
More informationPROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group
European Medicines Agency Inspections London, 20 April 2009 EMEA/INS/PhV/85058/2008 Procedure no: INS/PhV-V/2 PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP Ad Hoc PhV Inspectors
More informationPost Marketing PV AUDIT AND INSPECTION HOSTING. Michael Ramcharan Reumat Consulting Ejaz Butt ZigZag Associates
Post Marketing PV AUDIT AND INSPECTION HOSTING Michael Ramcharan Reumat Consulting Ejaz Butt ZigZag Associates Agenda Background Preparation Conduct Post Audit & Inspection CAPA Management Audit & Inspection
More informationMHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents
MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015 Deficiencies in GDP Phil Neale, GDP Operations Manager Tony Orme, GDP Senior Inspector. Finding deficiencies in GDP is not only for those
More informationPharmacovigilance System Master file
IMPLEMENTING MEASURES IN ORDER TO HARMONISE THE PERFORMANCE OF THE PHARMACOVIGILANCE ACTIVITIES PROVIDED FOR IN DIRECTIVE 2001/83/EC AND REGULATION (EC) NO 726/2004 Pharmacovigilance System Master file
More informationQualification and validation: - an inspector s perspective. Ian Rees, Unit Manager Inspectorate Strategy
Qualification and validation: - an inspector s perspective Ian Rees, Unit Manager Inspectorate Strategy GMP - basics A system within an organisation (or linked organisations) to assure the quality of its
More informationRecent developments in Pharmacovigilance from the Regulator s Perspective. In strategy, competence, quality and flexibility
Recent developments in Pharmacovigilance from the Regulator s Perspective In strategy, competence, quality and flexibility Pharmacovigilance Regulatory Affairs Operations Medical Writing & toxicology Recent
More informationModule VIII- Post-authorisation safety studies
Good Vigilance Practice Module VIII- Post-authorisation safety studies 4th Stakeholder Forum Xavier Kurz An agency of the European Union Post-authorisation safety study Any study relating to an authorised
More informationEarly Access to Medicines Scheme (EAMS)
Early Access to Medicines Scheme (EAMS) Safe and Timely Access to Medicines for Patients (STAMP) Dr Daniel O Connor May 2015 Expert Medical Assessor MHRA Early Access to Medicines A proposal for an Early
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and
More informationMHRA GPvP Symposium Summary 6 November 2015 Novotel Hotel, London
MHRA GPvP Symposium Summary 6 November 2015 Novotel Hotel, London Contents MHRA Symposium... page 03 Common Inspection Findings...page 04 Self-Governance...pages 05-06 SIGNAL Management...pages 07-08 RSI-
More informationNew pharmacovigilance systems and services
New pharmacovigilance systems and services 17 September 2015, PCWP/HCPWP joint meeting Presented by Peter Arlett, Head of Pharmacovigilance department An agency of the European Union Background The new
More informationRegulatory Requirements & Recent Changes, including expectations for APIs & IMPs
Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs Neil Raw - GMP Inspector Richard Andrews - Operations Manager 11 th November 2008 Programme: Regulatory Requirements Neil
More informationConsultation item no. 1 Should additional processes and pharmacovigilance tasks be covered? No, to our mind the list is complete.
Association Européenne des Spécialités Pharmaceutiques Grand Public Association of the European Self-Medication Industry Europäischer Verband der Arzneimittel-Hersteller AESGP Position Paper on the European
More informationUK Standards for Pharmacovigilance Departments 2015
UK Standards for Pharmacovigilance Departments 2015 03 UK Standards for Pharmacovigilance Departments 2015 Introduction 1 European legislation (Directive 2010/84/EU; Regulation (EU) No 1235/2010) requires
More informationImplementation of EU Falsified Medicines Directive
Implementation of EU Falsified Medicines Directive Gerald W Heddell Director, Inspection, Enforcement & Standards Division 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views
More informationDer Stufenplanbeaufragte / die QPPV:
Der Stufenplanbeaufragte / die QPPV: The EU Qualified Person for Pharmacovigilance Forum Online, 10. November 2010 Dr. Gernot Schreiber, Head Global Pharmacovigilance & Clinical Safety and EU QPPV Sandoz
More informationNew Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012
New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public
More informationPharmacovigilance System in India: Industry Perspective
Pharmacovigilance System in India: Industry Perspective Dr. Jamal Baig, Global Pharmacovigilance Country Leader, MSD Pharmaceutical Pvt. Ltd., India. Introduction Currently there are 3 major PV guidelines
More informationECMC Annual Network meeting
ECMC Annual Network meeting May 2017 Dr Kirsty Wydenbach Senior Clinical Assessor / CTU Deputy Unit Manager MHRA approach to assessing early phase cancer study protocols 2 in prinicpal no different to
More informationGood Documentation Practices. Documentation Requirements For Regulated Environments
Good Documentation Practices Documentation Requirements For Regulated Environments Agenda Example Deficiency 2014 Result Of Poor Record Creation Data Integrity EU GMP Chapter 4 Requirements Non GMP Compliant
More informationMHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents
MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015 Enforcement activities - Impact of the falsified medicines directive Presented by: Peter Blundell, GDP Inspector Impact of the falsified
More informationEMA Comments on Implementing Measures for Pharmacovigilance (PCIM/11/01)
7 November 2011 EMA/863255/2011 EMA Comments on Implementing for Pharmacovigilance (PCIM/11/01) The Agency welcomes the public consultation on the Commission concept paper on the implementing measures
More informationFOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS
FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS Document No. : FDA/SMC/SMD/GL-PVI/2013/02 Date of First Adoption : 1 st February, 2013 Date of Issue : 1 st March, 2013
More informationReport from EMA industry survey on Brexit preparedness
11 July 2018 EMA/450315/2018 Corr. 1 * * Date correction on page 4. Space removed on page 5. Space removed on page 6. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660
More informationPharmacovigilance Post July 2012 The new frontier
Pharmacovigilance Post July 2012 The new frontier Colleen Walsh Head, Safety and Benefit Risk Management Quality, Biogen Idec 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The
More informationMircea Ciuca, MD Global Head Medical & Clinical Drug Safety
Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor,
More informationEU Pharmacovigilance Legislation - One Year Later. Sarah Daniels; Senior Partner TranScrip Partners LLP
EU Pharmacovigilance Legislation - One Year Later Sarah Daniels; Senior Partner TranScrip Partners LLP Since July 2012 we have officially been operating under EU legislation Directive 2010/84/EU amending
More informationAgency and Internal Labeling
Agency and Internal Labeling Audits Joseph McMillian, MA Heartland Compliance Services LLC Internal Labeling Audits The views and opinions expressed in the following PowerPoint slides are those of the
More informationGood Vigilance Practice Module VI
Good Vigilance Practice Module VI Management and reporting of adverse reactions to medicinal products Stakeholders forum 27th February 2012 Gilles Touraille Signal Detection and Data Analysis Pharmacovigilance
More informationThe challenges of software medical device regulation.
The challenges of software medical device regulation. david.grainger@mhra.gov.uk Introduction A brief history of software device regulation A look at the new device regulations 2 Current framework In Vitro
More informationPharmacovigilance System in Russia and the EAEU
Pharmacovigilance System in Russia and the EAEU Authors: Sergey Simeniv CEO X7 Research, CRO; Olga Latysheva Head of Pharmacovigilance Department X7 Research, CRO; Dmitry Kryuchkov Executive Director X7
More informationPharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010
Pharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010 Content Legal basis What do agencies want? What happens Before During After How do you
More informationFeedback on EudraVigilance & new functionalities
Feedback on EudraVigilance & new functionalities 14th industry stakeholder platform operation of EU pharmacovigilance Anja van Haren (MEB), Sabine Brosch (EMA) and Francois Domergue (EMA) An agency of
More informationEudraVigilance stakeholder change management plan: integration with the Identity and Access Management (IAM2) project deliverables
24 May 2018 EMA/349760/2018 Information Management Division EudraVigilance stakeholder change management plan: integration with the Identity and Access Management (IAM2) project deliverables Pharmacovigilance
More informationSignal Management in the EU and future extended access to EudraVigilance for industry
Signal Management in the EU and future extended access to EudraVigilance for industry 6 th Industry Stakeholder Platform Meeting, 18 th December 2015 Presented by Georgy Genov 7 December 2015 Head of Signal
More informationEarlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot
Earlier Access to Medicines Early Access to Medicines Scheme and Adaptive Licensing pilot World Stem Cells & Regenerative Medicine 2014 Dr Daniel O Connor Disclaimer The views expressed do not necessarily
More informationEuropean Risk Management
European Risk Management Plans Issues and concerns from the generics sector John Barber QPPV & Director, Head of Pharmacovigilance European Operations, Dr. Reddy s Laboratories Europe Risk Management Plans
More informationPreparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties.
19 June 2018 CMDh/361/2017, Rev.2 Questions and Answers related to the United Kingdom's withdrawal from the European Union with regard to national authorised medicinal products for human use Introduction
More informationEudraVigilance auditable requirement project
22 November 2017 EMA/835422/2016 Information Management Division EudraVigilance training plan (version 5) Project Maintenance Group 1 consultation 11 December 2015 Eudravigilance Expert Working Group consultation
More informationBULGARIAN ASSOCIATION FOR DRUG INFORMATION (BADI)
1 BULGARIAN ASSOCIATION FOR DRUG INFORMATION (BADI) With the kind support from the Medical University - Sofia, organizes its regular autumn course on Pharmaceutical Regulations on the following topics
More informationGuidance on preparing for Brexit in the centralised procedure
Guidance on preparing for Brexit in the centralised procedure SME info day: Regulatory toolbox for medicines and combined devices developers Presented by Leonor Enes on 26 October 2018 SME Office, Stakeholders
More informationThe European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications
The European Commission's Proposal to Re-design Existing European Drug Safety Rules An Industry View on Practical Implications Margaret Walters Merck, Sharp & Dohme Ltd. The Second International Pharmaceutical
More informationHOT TOPICS IN PV. Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva
HOT TOPICS IN PV International Society of Pharmacovigilance Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva Dr Irene FERMONT, MD, MSc, EUQPPV ISOP ISRAEL Coordinator
More informationNew EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change
New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change Training Module PhV-M1 Overview of legal provisions that form the basis for the new EudraVigilance functionalities
More informationPharmacovigilance: Information systems and Services
Pharmacovigilance: Information systems and Services 3 rd Industry stakeholder platform operation of EU Pharmacovigilance legislation Presented by Peter Arlett Head of Pharmacovigilance Department An agency
More informationRe: PCIM/11/01 Public Consultation on Implementing Measures for Pharmacovigilance
07 November 2011 By email: sanco pharmaceuticals@ec.europa.eu Directorate General for Health and Consumers Unit SANCO/D/3 BE 1049 Brussels Belgium Dear Sirs, Re: PCIM/11/01 Public Consultation on Implementing
More informationWhat is an ideal PSUR? A new focus based on aligned expectations
What is an ideal PSUR? A new focus based on aligned expectations Margarida Guimarães PRAC Member INFARMED, I.P. Periodic Safety Update Report Information Day 28 October 2016 London, UK Disclaimer The views
More informationQ&A ROYAL DECREE OF 28 MAY 2013 AND CIRCULAR LETTER N 601
Q&A ROYAL DECREE OF 28 MAY 2013 AND CIRCULAR LETTER N 601 1. What procedure should be followed to notify someone as a local contact person at the famhp and what requirements does the contact person need
More informationEudraVigilance: Preparing for Change
EudraVigilance: Preparing for Change EudraVigilance Auditable Requirement project 6 th Industry Stakeholder Platform Meeting, 18 th December 2015 Presented by Francois Domergue, Data Standardisation and
More informationEudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia
EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia Presented by: Vladimir Raketić, DVM, spec; Audit /QM group Ministry of Agriculture, Forestry and Water Managment, Veterinary
More informationBrexit Guidance for Stakeholders Human and veterinary medicines
Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject
More informationWholesaling & Distribution & the GMPs
Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the
More informationWholesaling & Distribution & the GMPs
Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the
More informationPresenter: Ejaz Butt
Presenter: Ejaz Butt Disclaimer The content and opinions expressed in the following PowerPoint slides are those of individuals who prepared the presentation and should not be attributed to Zigzag Associates
More informationInspection findings on Health Based Exposure Limits and Cross Contamination. Graeme McKilligan, UK, MHRA.
Inspection findings on Health Based Exposure Limits and Cross Contamination Graeme McKilligan, UK, MHRA. Content Some Metrics Key issues encountered Examples of deficiencies Key challenges for inspectors
More informationInterdependencies of Pharmacovigilance and Regulatory Affairs
Lorenz userbridge 2013 Budapest, September 17th Interdependencies of Pharmacovigilance and Regulatory Affairs Dr. rer. nat. Markus Dehnhardt Deputy QPPV Biologist Toxicologist Medical advisor Agenda 1.
More informationGuidelines on good pharmacovigilance practices (GVP)
15 September 2014 EMA/475236/2014 Guidelines on good pharmacovigilance practices (GVP) Introductory cover note, last updated with revision 1 of module III on pharmacovigilance inspections and of module
More informationCompetence in Clinical Trials the Regulators Perspective.. (Jennifer Martin Senior GCP Inspector, 9 June 2014)
Competence in Clinical Trials the Regulators Perspective. (Jennifer Martin Senior GCP Inspector, 9 June 2014) Requirements Statutory Instrument 2004/1031 (as amended) Regulation 28(2): The sponsor (and
More informationDoc. No. DPS/GDL/034 Revision No.: 0 Effective Date: 26 April 2018 Review-Due Date: 26 April 2021
National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda Tel: 256-0414 - 255665/347391/2 E-mail: ndaug@nda.or.ug Website: http://www.nda.or.ug Doc. No. DPS/GDL/034
More informationFormat and content of electronic periodic safety update reports (Technical contribution to EC implementing measure)
Format and content of electronic periodic safety update reports (Technical contribution to EC implementing measure) First Stakeholders Forum on the implementation of the new Pharmacovigilance legislation,
More informationImplementing the New Pharmacovigilance Legislation
Implementing the New Pharmacovigilance Legislation Irish Medicines Board, Pharmacovigilance Information Day, Dec 2011 Dr. Almath Spooner Vigilance Assessment Manager, Human Products Monitoring Department
More informationInspection of API Manufacturers & Update on Registration Process
Inspection of API Manufacturers & Update on Registration Process Catherine Neary, GMP Inspector GMP Conference 7 February 2017 Dublin Presentation Contents HPRA Inspection Programme for API Manufacturers
More informationFOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE
FOOD AND DRUGS AUTHORITY GUIDELINES FOR QUALIFIED PERSON FOR PHARMACOVIGILANCE Document No. : Date of First Adoption : 1st February, 2013 Date of Issue : 1 st March, 2013 Version No. : 02 Revision 1 :
More informationPHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use
PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use This guideline replaces PHV-3 guideline version 3 effective from 11. 01. 2016 The guideline provides
More informationComparability: Regulatory Perspective
Comparability: Regulatory Perspective Louise Bisset PhD Pharmaceutical Assessor Biological Medicinal Products (Drug Product Licensing) PSCP workshop 14-15 th Sept 2015, Cambridge. Outline Introduction
More informationMedical Literature Monitoring
Medical Literature Monitoring 5 th Industry Platform on the implementation of EU pharmacovigilance legislation Presented by Tom Paternoster-Howe on 15 September 2015 EMA/Information Management/Data Standardisation
More informationGuidelines on good pharmacovigilance practices (GVP)
7 June 2013 EMA/321625/2013 Patient Health Protection Guidelines on good pharmacovigilance practices (GVP) Introductory cover note, last updated with launch of public consultation of module VI revision
More informationCMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures
October 2017 CMDh/004/2005/Rev.15 CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Table of contents (optional) 1. Introduction... 2 2. Legal framework...
More informationNAFDAC GOOD PHARMACOVIGILANCE
NAFDAC GOOD PHARMACOVIGILANCE PRACTICE GUIDELINES 2016 NAFDAC GOOD PHARMACOVIGILANCE PRACTICE GUIDELINES 2016 NATIONAL AGENCY FOR FOOD AND DRUG NAFDAC NAFDAC GOOD PHARMACOVIGILANCE PRACTICE GUIDELINES
More informationGVP Module IX: Signal Management
27 February 2012 4 th Stakeholders Forum Presented by: Agnieszka Szmigiel Pharmacovigilance and Risk Management Sector, EMA An agency of the European Union Topics Scope of Module IX Signal Management (SM)
More informationGood Pharmacovigilance Practice Tunisian guidelines
Good Pharmacovigilance Practice Tunisian guidelines Introduction Arab ministers of health came to a common decree (number 7) in their 37th regular meeting in March 2012. The Higher Technical Committee
More informationNIS Considerations - Bulgaria
NIS Considerations - Bulgaria An overview of the considerations when conducting Noninterventional Studies in Bulgaria Stuart McCully CHCUK Ltd NIS-C-BG-2014 1 Table of Contents Disclaimer 5 Copyright 5
More informationAnnex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO
23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,
More informationGuidelines on good pharmacovigilance practices (GVP)
12 April 2013 EMA/131811/2013 Patient Health Protection Guidelines on good pharmacovigilance practices (GVP) Introductory cover note, last updated with revision of module II, launch of public consultation
More informationA practical guide to achieving and maintaining global oversight and ensuring end-to-end pharmacovigilance
FOR PHARMA & LIFE SCIENCES WHITE PAPER A practical guide to achieving and maintaining global oversight and ensuring end-to-end pharmacovigilance The increasing complexity of today s pharmaceutical industry
More informationBrexit info meeting. 5 February 2018
Brexit info meeting 5 February 2018 1 Agenda Introduction Brexit from a pharmaceutical perspective Practical aspects Variations Change of RMS Reference product from UK Q&A session Coffee and possibility
More informationExplanatory Note to GVP Module VII
31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure
More informationEffective Auditing of PV Interfaces
Outline Effective Auditing of PV Interfaces SQA Meeting March 29, 2017 Larry Thomas, RQAP-GLP, CQA Bayer Pharmaceuticals Whippany, NJ Audit Process Planning/Preparation, Execution and Reporting Functions
More informationEMA pharmacovigilance system manual
13 October 2016 EMA/623550/2013 Inspections, Human Medicines Pharmacovigilance & Committees Division Version 1.2 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000
More informationEXPERT ISE YOU CAN TRUST
EXPERT ISE YOU CAN TRUST 03 Contents INTRODUCTION 04 THIS IS WHO WE ARE 06 THIS IS WHAT WE DO 08 OUR SERVICES 10 Regulatory Strategy Services 12 Product Registrations & Maintenance 13 Electronic Publishing
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/813938/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 3) Date for coming into effect of first version 2 July 2012
More information